Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung
| Main Authors: | Thuzar Kyin Aung, Htar Kyi Sunn, Theingi Myint |
|---|---|
| Format: | Article eJournal |
| Terbitan: |
, 2016
|
| Online Access: |
https://zenodo.org/record/3678115 |
Daftar Isi:
- Relation of inflammation and cancer can be proven in most of the studies. Epidermal growth factor receptor (EGFR) overexpression is one of the commonest causes of non-small cell carcinoma of lung cancer (NSCLC). Cyclooxygenase-2 (COX-2) enzyme and its products; prostaglandin, prostacyclin, thromboxane are involved in inflammation. The aim of the study was to determine the association between serum EGFR and cyclooxygenase-2 levels in patients with NSCLC and healthy controls. It was a cross-sectional analytic study. This study included 53 patients diagnosed as NSCLC (3 adenocarcinoma and 50 squamous cell carcinoma (SCC) of lung patients) and 16 apparently controls. Serum EGFR and COX-2 levels were determined by ELISA. Serum EGFR levels of healthy controls and NSCLC patients were 3.56±0.48 ng/ml and 170.10±13.80 ng/ml, respectively. In patients with NSCLC, serum EGFR of SCC and adenocarcinoma lung were 172.10±14.30 ng/ml and 137.40 ±64.70 ng/ml, respectively. Serum COX-2 levels of healthy controls and NSCLC patients were 0.62±0.15 ng/ml and 13.21±3.17 ng/ml. In patients with NSCLC, serum COX-2 levels of SCC and adenocarcinoma lung were 13.60±3.34 ng/ml and 6.69±5.52 ng/ml, respectively. There is a significant association between serum EGFR and COX-2 levels in NSCLC patients (X2 = 7.854, p = 0.005). Mean level of serum EGFR (170.10 ng/ml) and COX-2 (13.21 ng/ml) are set as cut off values for categorization of low and high groups. There was no correlation between serum EGFR and COX-2 in healthy controls (r = -0.036, p = 0.894) and NSCLC patients (r = 0.161, p = 0.250). After excluding 4 outliers, the correlation between serum EGFR and COX-2 levels in NSCLC patients became significant (r = 0.454, p = 0.001). Correlation between serum EGFR and COX-2 levels in SCC patients was not significant statistically (r = 0.142, p = 0.325) but after excluding the 4 outliers, it became significant statistically (r = 0.418, p = 0.004). There was positive correlation in adenocarcinoma (r = 0.999, p = 0.021). These findings indicated that EGFR and COX-2 play an important role in carcinogenesis of lung and are positively associated.